Scarica l'app Stockscreener
30.34
2.35%
-0.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Sentiment Watch: Should I hold or sell Stoke Therapeutics Inc nowJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Breakouts Watch: Does FULT outperform in volatile marketsJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options - Nasdaq
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 27.53% Upside Potential In Biotech - DirectorsTalk Interviews
Stoke Therapeutics (NASDAQ:STOK) Trading 6.2% HigherHere's What Happened - MarketBeat
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters - TipRanks
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Finviz
Huge Waltham lab lease fuels work on potential Dravet syndrome drug - Stock Titan
Stoke Therapeutics Shares Face Pressure from Strategic Expansion - AD HOC NEWS
Understanding Momentum Shifts in (STOK) - Stock Traders Daily
Should value investors consider Stoke Therapeutics Inc2025 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Stoke Therapeutics (STOK) Stock Analysis: Unveiling Growth Potential with a 23.54% Upside - DirectorsTalk Interviews
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position - MarketBeat
Trial testing breakthrough Dravet drug zorevunersen now nearly full - Dravet Syndrome News
Stoke Therapeutics (STOK) price target increased by 10.42% to 36.46 - MSN
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics (STOK) Price Target Increased by 10.42% to 36.46 - Nasdaq
STOK: Phase III for Dravet therapy nears full enrollment, with durable efficacy and regulatory momentum - TradingView — Track All Markets
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Phase III update Stokes hope; Dravet game-change Encoded? - BioWorld MedTech
Wedbush Raises Price Target for Stoke Therapeutics (STOK) to $36 - GuruFocus
Stoke Therapeutics Says US FDA Seeks Additional Information for Zorevunersen in Dravet Syndrome; Shares Fall - marketscreener.com
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline By Investing.com - Investing.com Nigeria
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $36.00 at Wedbush - MarketBeat
8 Analysts Have This To Say About Stoke Therapeutics - Benzinga
Stoke Therapeutics (NASDAQ: STOK) sees cash runway into 2028 operations - Stock Titan
Some Analysts Just Cut Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Estimates - 富途资讯
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - The AI Journal
Stoke Therapeutics Targets Mid-2027 Phase 3 Readout To Support FDA Filing Of Zorevunersen - Nasdaq
Biogen (BIIB) Advances with Zorevunersen Development Program - GuruFocus
Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen - TradingView — Track All Markets
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Strong Buy Ratings Amid Impressive Revenue Growth and Promising Pipeline - DirectorsTalk Interviews
Why hedge funds are buying Stoke Therapeutics Inc. stockGrip and Outsole Review & size guide reminders to avoid returns - ulpravda.ru
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - Улправда
Is Stoke Therapeutics Inc. stock a buy in volatile marketsQuarterly Market Review & Fast Gaining Stock Strategy Reports - Улправда
Fed Meeting: Is Stoke Therapeutics Inc. stock vulnerable to regulatory risksMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
Breakouts Watch: Will Stoke Therapeutics Inc. stock gain from strong economyQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - ulpravda.ru
EBIT per share of Stoke Therapeutics, Inc. – MUN:0GT - TradingView — Track All Markets
Los Angeles Daily NewsStoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Tangible book value per share of Stoke Therapeutics, Inc. – DUS:0GT - TradingView — Track All Markets
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Cantor Fitzgerald reiterates Overweight rating on Stoke Therapeutics stock By Investing.com - Investing.com Canada
Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital - MarketBeat
Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News - GuruFocus
Chardan Capital Markets assumes coverage on Stoke Therapeutics stock with Buy rating - Investing.com Canada
Discipline and Rules-Based Execution in STOK Response - Stock Traders Daily
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week - Yahoo Finance
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):